Medicenna Therapeutics Income Statement

Financials in millions CAD. Fiscal year is April - March.

Millions CAD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Selling, General & Admin	5.53	5.96	7.87	7	7.76
Research & Development	16.88	14.44	10.8	9.3	14.72
Operating Expenses	22.42	20.41	18.67	16.3	22.47
Operating Income	-22.42	-20.41	-18.67	-16.3	-22.47
Interest & Investment Income	0.53	1.35	1.2	0.91	0.07
Currency Exchange Gain (Loss)	-0.8	0.9	-0.07	1.65	-0.17
Other Non Operating Income (Expenses)	4.28	6.35	-7.92	3.7	-
EBT Excluding Unusual Items	-18.41	-11.81	-25.47	-10.05	-22.58
Pretax Income	-18.41	-11.81	-25.47	-10.05	-22.58
Net Income	-18.41	-11.81	-25.47	-10.05	-22.58
Net Income to Common	-18.41	-11.81	-25.47	-10.05	-22.58
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	83	77	70	65	54
Shares Outstanding (Diluted)	83	77	70	65	54
Shares Change	8.51%	10.10%	7.57%	19.25%	9.31%
EPS (Basic)	-0.22	-0.15	-0.37	-0.16	-0.42
EPS (Diluted)	-0.22	-0.15	-0.37	-0.16	-0.42
EPS Growth	-	-	-	-	-
Free Cash Flow	-17.92	-16.53	-16.26	-12.66	-23.58
Free Cash Flow Per Share	-0.21	-0.22	-0.23	-0.20	-0.43
EBITDA	-22.4	-20.39	-18.67	-16.3	-22.44
D&A For EBITDA	0.02	0.02	0	0	0.04
EBIT	-22.42	-20.41	-18.67	-16.3	-22.47